Last reviewed · How we verify
Gram-Negative Aerobic Bacillary Pneumonia
Approved treatments
- Ramycin
Fusidic acid works by inhibiting the function of the bacterial ribosome, preventing the production of essential proteins. - Garamycin · Merck & Co.
- Tobi · Novartis
- Ciprofloxacine · Poitiers University Hospital
- Vantobra · Pfizer
- Gentamicin · Merck & Co.
- Nebcin · University Hospital, Lille
- Ceftriaxon · Centre Hospitalier Universitaire Vaudois
- Azactam · Bristol-Myers Squibb
Aztreonam inhibits bacterial cell wall synthesis, acting as a bactericidal agent. - Primaxin · Merck Sharp & Dohme B.V.
Primaxin works by inhibiting bacterial cell wall synthesis, ultimately leading to bacterial cell death. - Arikayce Kit · Bristol-Myers Squibb
Amikacin works by binding to bacterial ribosomes, inhibiting protein synthesis and ultimately killing the bacteria. - Primaxin · Merck & Co.
Primaxin works by inhibiting the action of dehydropeptidase, an enzyme that breaks down certain antibiotics, thereby protecting them from degradation and allowing them to reach effective concentrations in the body. - Noroxin
- Floxin
- Cipro · Bayer AG
- Rocephin · Generic (originally Roche)
- Levaquin · Generic (originally Daiichi Sankyo/J&J)
Levofloxacin is a fluoroquinolone antibacterial agent. - Ofloxacine · Assistance Publique - Hôpitaux de Paris
Competitive intelligence
For the full treatment-landscape CI brief — marketed leaders side-by-side, pipeline by phase, recent regulatory actions, sponsor landscape:
- Gram-Negative Aerobic Bacillary Pneumonia patent landscape — cliff calendar, originator estates, attackable patents
- Gram-Negative Aerobic Bacillary Pneumonia treatment landscape brief
- Gram-Negative Aerobic Bacillary Pneumonia treatment updates RSS
Frequently asked questions about Gram-Negative Aerobic Bacillary Pneumonia
What drugs treat Gram-Negative Aerobic Bacillary Pneumonia?
Tracked treatments include Ramycin, Garamycin, Tobi, Ciprofloxacine, Vantobra, Gentamicin, Nebcin, Ceftriaxon.
What is the treatment for Gram-Negative Aerobic Bacillary Pneumonia?
Standard treatment for Gram-Negative Aerobic Bacillary Pneumonia includes Ramycin, Garamycin, Tobi, Ciprofloxacine, Vantobra. See the treatment landscape page for first-line, second-line and salvage options.
Related
- Treatment landscape: Gram-Negative Aerobic Bacillary Pneumonia patent cliff · Gram-Negative Aerobic Bacillary Pneumonia CI report
- Treatment: Ramycin
- Treatment: Garamycin · Merck & Co.
- Treatment: Tobi · Novartis
- Treatment: Ciprofloxacine · Poitiers University Hospital
- Treatment: Vantobra · Pfizer
- All diseases: Browse the disease index · Disease landscape hub
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing